Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus

Summary

The study is aimed to evaluate the safety and efficiency of autologous bone marrow mononuclear cell transplantation in treating selective patients with type 2 Diabetes Mellitus. We hypothesized that autologous bone marrow stem cell transplantation would promote β-cells regeneration by directly differentiated from the transplanted BMMCs or stimulate local stem cells regeneration and thus decrease or eliminate the need of exogenous insulin and improve β-cells function.

Conditions

• Type 2 Diabetes Mellitus

Interventions

OTHER

BMMCT

Bone marrow mononuclear cell transplantation via selective catheterization

Sponsors & Collaborators

• Peking University Aerospace Center Hospital

  lead OTHER

Principal Investigators

• Yizhong Wang, M.D., Ph.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Yuanjie Mao, M.D., Ph.D. · Department of Biochemisty, National Cerebral and Cardiovascular Center; Department of Cardiology, China-Japan Friendship Hospital

• Lei Lei, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Danping Meng, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Xiyang Zhang, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Xiaolin Jia, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Qiuming Jiang, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Yufang Li, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Song Dong, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Liyan Yang, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Hong Wang, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Mingchao Ding, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Liqin Cui, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Bin Wang, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Xin Lin, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

• Han Shi, M.D. · Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

30 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-05-31

Primary Completion

2015-05-31

Completion

2017-07-31

Countries

• China

Study Locations